Research programme: cannabidiol based therapeutics - CV Sciences

Drug Profile

Research programme: cannabidiol based therapeutics - CV Sciences

Alternative Names: Cannabidiol - CV Sciences; CVSI-007

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator CanX
  • Developer CV Sciences, Inc
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Smoking withdrawal

Most Recent Events

  • 19 Jun 2017 CV Sciences announces intention to submit an IND to US FDA for CVSI 007 for Smoking withdrawal
  • 31 Mar 2017 CV Sciences has patents pending for CVSI 007 in USA (CV Sciences 10-K filed in March 2017)
  • 02 Nov 2016 Preclinical trials in Smoking withdrawal in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top